Geron licenses MaxCyte's cell loading technology for use in cancer vaccine

By Lisa Kerner

Erie, Pa., Feb. 15 - MaxCyte, Inc. and Geron Corp. announced a license, option, development and supply agreement to use MaxCyte's proprietary cell loading system in the manufacture of mRNA-loaded dendritic cell-based vaccines, including Geron's GRNVAC1 therapeutic cancer vaccine.

The agreement provides Geron with access to MaxCyte's GMP-compliant cell loading technology for use in closed-system manufacturing of GRNVAC, according to a company news release.

In addition, the agreement provides an option for a commercial license to MaxCyte's technology and a supply contract, as well as rights to reference MaxCyte's Food and Drug Administration Master File in Geron's regulatory submissions.

"The GRNVAC1 program has already produced extremely promising clinical data in phase 1/2 clinical trials at Duke University. We are developing a closed system manufacturing process which will allow us to improve scalability, and reduce cost as we continue to move this program through clinical trials," Thomas B. Okarma, Geron's president and chief executive officer, said in the release.

"Based upon its impressive capabilities, we believe MaxCyte's cell loading technology can be an important component of our closed system," he added.

MaxCyte is a clinical-stage cell therapeutics company based in Gaithersburg, Md.

Geron is a biopharmaceutical company developing and commercializing products for oncology, injury, degenerative disease and multiple chronic diseases. The company is located in Menlo Park, Calif.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.